| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $17.6M | — | -34.1% |
| SG&A Expense | $17.6M | — | +166.5% |
| Operating Income | -$35.2M | — | -5.6% |
| Net Income | -$219.6M | — | -575.9% |
| EPS (Basic) | -$5.11 | — | -1865.4% |
| EPS (Diluted) | -$5.11 | — | -1865.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $169.9M | -57.2% | +239.4% |
| Short-term Investments | $321.7M | +447.8% | +3120.4% |
| Current Assets | $500.8M | +9.3% | +672.2% |
| Total Assets | $506.7M | +9.2% | +363.6% |
| Current Liabilities | $16.1M | -36.1% | -3.9% |
| Total Liabilities | $657.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$38.2M | — | -23.1% |
| Capital Expenditures | $48K | — | -79.2% |
| Investing Cash Flow | -$263.2M | — | — |
| Financing Cash Flow | $74.9M | — | — |
| Free Cash Flow | -$38.3M | — | -22.4% |
| +1419.7% |
| Stockholders' Equity | -$150.4M | +8.5% | -327.7% |